Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 7/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.50 |
| ▸ | MAPK14 | Q16539 | 10/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | HPGD | P15428 | 2/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | GLA | P06280 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | CASP1 | P29466 | 1/20 | 0.42 |
| ▸ | CASP7 | P55210 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8720509 | 0.85 | LMNA (0.51) | KDM4EALDH1A1MAPK14LMNAHSD17B10 | |
| SCHEMBL8720568 | 0.85 | KDM4E (0.47) | KDM4EALDH1A1MAPK14LMNAHSD17B10 | |
| SCHEMBL20053799 | 0.82 | KDM4E (0.49) | KDM4EALDH1A1LMNAHSD17B10KMT2A | |
| SCHEMBL12797606 | 0.82 | KDM4E (0.49) | KDM4EALDH1A1MAPK14LMNAHSD17B10 | |
| SCHEMBL19861782 | 0.80 | KDM4E (0.50) | KDM4EALDH1A1MAPK14LMNAHSD17B10 | |
| SCHEMBL21237806 | 0.79 | KDM4E (0.50) | KDM4EALDH1A1LMNAHSD17B10KMT2A | |
| SCHEMBL19297200 | 0.79 | KDM4E (0.48) | KDM4EALDH1A1LMNAHSD17B10KMT2A | |
| SCHEMBL19297194 | 0.77 | KDM4E (0.44) | KDM4EALDH1A1LMNAHSD17B10KMT2A | |
| SCHEMBL22958087 | 0.76 | KDM4E (0.43) | KDM4EALDH1A1LMNAHSD17B10KMT2A | |
| SCHEMBL20858133 | 0.74 | KDM4E (0.45) | KDM4EALDH1A1LMNAHSD17B10KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 109 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12023385-B2 | Tunable endogenous protein degradation with heterobifunctional compounds | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2024-07-02 | — | — | US | disclosed |
| US-20240025898-A1 | HPK1 ANTAGONISTS AND USES THEREOF | SCHRÖDINGER, INC. | 2024-01-25 | — | — | US | disclosed |
| US-20240025898-A1 | HPK1 ANTAGONISTS AND USES THEREOF | SCHRÖDINGER, INC. | 2024-01-25 | — | — | US | disclosed |
| US-11834455-B2 | Carm1 inhibitors and uses thereof | Epizyme, Inc. (US) | 2023-12-05 | — | — | US | disclosed |
| US-11834455-B2 | Carm1 inhibitors and uses thereof | Epizyme, Inc. (US) | 2023-12-05 | — | — | US | disclosed |
| US-11787796-B2 | Plasma Kallikrein inhibitors and uses thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2023-10-17 | — | — | US | disclosed |
| US-11787796-B2 | Plasma Kallikrein inhibitors and uses thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2023-10-17 | — | — | US | disclosed |
| US-20230322747-A1 | OXADIAZOLE HDAC6 INHIBITORS AND USES THEREOF | EIKONIZO THERAPEUTICS, INC. (US) | 2023-10-12 | — | — | US | disclosed |
| WO-2023196601-A1 | OXADIAZOLE HDAC6 INHIBITORS AND USES THEREOF | EIKONIZO THERAPEUTICS, INC. (US) | 2023-10-12 | — | — | WO | disclosed |
| US-20230322747-A1 | OXADIAZOLE HDAC6 INHIBITORS AND USES THEREOF | EIKONIZO THERAPEUTICS, INC. (US) | 2023-10-12 | — | — | US | disclosed |
| US-7799801-B2 | Heterocyclic aromatic compounds useful as growth hormone secretagogues | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-09-21 | — | — | US | disclosed |
| US-20100016233-A1 | Heterocyclic Aromatic Compounds Useful As Growth Hormone Secretagogues | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-01-21 | — | — | US | disclosed |
| US-20090324625-A1 | Heterocyclic Aromatic Compounds Useful As Growth Hormone Secretagogues | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-12-31 | — | — | US | disclosed |
| US-20090324625-A1 | Heterocyclic Aromatic Compounds Useful As Growth Hormone Secretagogues | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-12-31 | — | — | US | disclosed |
| US-7592354-B2 | Heterocyclic aromatic compounds useful as growth hormone secretagogues | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-09-22 | — | — | US | disclosed |
| US-7589102-B2 | Heterocyclic aromatic compounds useful as growth hormone secretagogues | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-09-15 | — | — | US | disclosed |
| US-7166596-B2 | Heterocyclic aromatic compounds useful as growth hormone secretagogues | BRISTOL-MYERS SQUIBB CO. (US) | 2007-01-23 | — | — | US | disclosed |
| US-7166596-B2 | Heterocyclic aromatic compounds useful as growth hormone secretagogues | BRISTOL-MYERS SQUIBB CO. (US) | 2007-01-23 | — | — | US | disclosed |
| EP-1601672-A1 | TRIAZOLO-PYRIDINES AS ANTI-INFLAMMATORY COMPOUNDS | Pfizer Products Inc. (US) | 2005-12-07 | — | — | EP | disclosed |
| WO-2004072072-A1 | TRIAZOLO-PYRIDINES AS ANTI-INFLAMMATORY COMPOUNDS | PFIZER PRODUCTS INC. (US) | 2004-08-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230322747-A1 | OXADIAZOLE HDAC6 INHIBITORS AND USES THEREOF | HDAC6, HDAC1, HDAC11 | KDM4E 2674/4885ALDH1A1 755/4885MAPK14 2496/4885 |
| US-20090324625-A1 | Heterocyclic Aromatic Compounds Useful As Growth Hormone Secretagogues | GHSR, GHRHR, NPY1R | KDM4E 1038/4885ALDH1A1 3846/4885MAPK14 2185/4885 |
| US-20100016233-A1 | Heterocyclic Aromatic Compounds Useful As Growth Hormone Secretagogues | GHSR, GHRHR, NPY1R | KDM4E 1038/4885ALDH1A1 3846/4885MAPK14 2185/4885 |
| US-12023385-B2 | Tunable endogenous protein degradation with heterobifunctional compounds | DBN1, MYCBP, PSMG3 | KDM4E 4017/4885ALDH1A1 4238/4885MAPK14 4332/4885 |
| US-11787796-B2 | Plasma Kallikrein inhibitors and uses thereof | KLKB1, KLK1, KLK5 | KDM4E 813/4885ALDH1A1 3007/4885MAPK14 1691/4885 |
| US-20240025898-A1 | HPK1 ANTAGONISTS AND USES THEREOF | PDXK, HIPK1, PCK1 | KDM4E 3143/4885ALDH1A1 4740/4885MAPK14 503/4885 |
| US-11834455-B2 | Carm1 inhibitors and uses thereof | CARM1, TIAM1, ADRM1 | KDM4E 1077/4885ALDH1A1 2184/4885MAPK14 3281/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.